A citation-based method for searching scientific literature

Ilanah J Pruis, Stephan R Koene, Sebastian R van der Voort, Fatih Incekara, Arnaud J P E Vincent, Martin J van den Bent, Geert J Lycklama À Nijeholt, Rishi D S Nandoe Tewarie, Sophie E M Veldhuijzen van Zanten, Marion Smits. Neurooncol Adv 2022
Times Cited: 3







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree, Dominique Figarella-Branger, Cynthia Hawkins, H K Ng, Stefan M Pfister, Guido Reifenberger,[...]. Neuro Oncol 2021
66

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Kevin Leu, Garrett A Ott, Albert Lai, Phioanh L Nghiemphu, Whitney B Pope, William H Yong, Linda M Liau, Timothy F Cloughesy, Benjamin M Ellingson. J Neurooncol 2017
84
66

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
66

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
66

T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
Sohil H Patel, Laila M Poisson, Daniel J Brat, Yueren Zhou, Lee Cooper, Matija Snuderl, Cheddhi Thomas, Ana M Franceschi, Brent Griffith, Adam E Flanders,[...]. Clin Cancer Res 2017
166
66

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick,[...]. Acta Neuropathol 2009
814
33

Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Anh N Tran, Albert Lai, Sichen Li, Whitney B Pope, Stephanie Teixeira, Robert J Harris, Davis C Woodworth, Phioanh L Nghiemphu, Timothy F Cloughesy, Benjamin M Ellingson. Neuro Oncol 2014
64
33

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013
814
33

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.
James R Anderson, Kevin C Cain, Richard D Gelber. J Clin Oncol 2008
174
33

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Farshad Farshidfar, Siyuan Zheng, Marie-Claude Gingras, Yulia Newton, Juliann Shih, A Gordon Robertson, Toshinori Hinoue, Katherine A Hoadley, Ewan A Gibb, Jason Roszik,[...]. Cell Rep 2017
270
33

Management of low-grade glioma: a systematic review and meta-analysis.
Timothy J Brown, Daniela A Bota, Martin J van Den Bent, Paul D Brown, Elizabeth Maher, Dawit Aregawi, Linda M Liau, Jan C Buckner, Michael Weller, Mitchel S Berger,[...]. Neurooncol Pract 2019
48
33

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Benjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, Raymond Y Huang, Rivka Colen, Lauren E Abrey, Dana T Aftab, Gisela M Schwab, Colin Hessel, Robert J Harris,[...]. Clin Cancer Res 2017
43
33

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, Elizabeth Maher, Macarena I De La Fuente, Matthias Holdhoff, Gregory M Cote, Howard Burris, Filip Janku, Robert J Young,[...]. J Clin Oncol 2020
91
33

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
M J van den Bent, J S Wefel, D Schiff, M J B Taphoorn, K Jaeckle, L Junck, T Armstrong, A Choucair, A D Waldman, T Gorlia,[...]. Lancet Oncol 2011
341
33

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Hui Yang, Dan Ye, Kun-Liang Guan, Yue Xiong. Clin Cancer Res 2012
254
33

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Ingo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, Howard A Burris, Elizabeth A Maher, Filip Janku, Gregory M Cote, Macarena I de la Fuente, Jennifer L Clarke, Benjamin M Ellingson,[...]. Clin Cancer Res 2021
45
33

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.
Benjamin M Ellingson, Martin Bendszus, Jerrold Boxerman, Daniel Barboriak, Bradley J Erickson, Marion Smits, Sarah J Nelson, Elizabeth Gerstner, Brian Alexander, Gregory Goldmacher,[...]. Neuro Oncol 2015
311
33

Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
Joseph Song, Priyanka Kadaba, Amanda Kravitz, Adilia Hormigo, Joshua Friedman, Puneet Belani, Constantinos Hadjipanayis, Benjamin M Ellingson, Kambiz Nael. Neuro Oncol 2020
15
33

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn,[...]. Blood 2017
831
33

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Jan C Buckner, Edward G Shaw, Stephanie L Pugh, Arnab Chakravarti, Mark R Gilbert, Geoffrey R Barger, Stephen Coons, Peter Ricci, Dennis Bullard, Paul D Brown,[...]. N Engl J Med 2016
536
33

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Philipp Kickingereder, Benedikt Wiestler, Sina Burth, Antje Wick, Martha Nowosielski, Sabine Heiland, Heinz-Peter Schlemmer, Wolfgang Wick, Martin Bendszus, Alexander Radbruch. Neuro Oncol 2015
68
33

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Albert Lai, Samir Kharbanda, Whitney B Pope, Anh Tran, Orestes E Solis, Franklin Peale, William F Forrest, Kanan Pujara, Jose A Carrillo, Ajay Pandita,[...]. J Clin Oncol 2011
317
33

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Gail J Roboz, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Alice S Mims, Gabrielle T Prince, Jessica K Altman, Martha L Arellano, Will Donnellan, Harry P Erba,[...]. Blood 2020
167
33

Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.
Warren Chang, Whitney B Pope, Robert J Harris, Anthony J Hardy, Kevin Leu, Reema R Mody, Phioanh L Nghiemphu, Albert Lai, Timothy F Cloughesy, Benjamin M Ellingson. Tomography 2015
9
33

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
33

Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study.
M Klein, J J Heimans, N K Aaronson, H M van der Ploeg, J Grit, M Muller, T J Postma, J J Mooij, R H Boerman, G N Beute,[...]. Lancet 2002
388
33

Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas.
Jerrold L Boxerman, Chad C Quarles, Leland S Hu, Bradley J Erickson, Elizabeth R Gerstner, Marion Smits, Timothy J Kaufmann, Daniel P Barboriak, Raymond H Huang, Wolfgang Wick,[...]. Neuro Oncol 2020
50
33


Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement.
Nicholas Cho, Chencai Wang, Catalina Raymond, Tania Kaprealian, Matthew Ji, Noriko Salamon, Whitney B Pope, Phioanh L Nghiemphu, Albert Lai, Timothy F Cloughesy,[...]. J Neurooncol 2020
5
33

Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice.
Jerrold L Boxerman, Mark S Shiroishi, Benjamin M Ellingson, Whitney B Pope. Magn Reson Imaging Clin N Am 2016
30
33

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
Tareq A Juratli, Matthias Kirsch, Katja Robel, Silke Soucek, Kathrin Geiger, Rüdiger von Kummer, Gabriele Schackert, Dietmar Krex. J Neurooncol 2012
71
33

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
337
33

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018
744
33

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Sadudee Chotirat, Wanna Thongnoppakhun, Orathai Promsuwicha, Chetsada Boonthimat, Chirayu U Auewarakul. J Hematol Oncol 2012
69
33

Lactate dehydrogenase A silencing in IDH mutant gliomas.
Charles Chesnelong, Myriam M Chaumeil, Michael D Blough, Mohammad Al-Najjar, Owen D Stechishin, Jennifer A Chan, Russell O Pieper, Sabrina M Ronen, Samuel Weiss, H Artee Luchman,[...]. Neuro Oncol 2014
123
33

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
T L Chenevert, L D Stegman, J M Taylor, P L Robertson, H S Greenberg, A Rehemtulla, B D Ross. J Natl Cancer Inst 2000
504
33

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen, Evanthia Galanis, John Degroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman,[...]. J Clin Oncol 2010
33

User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability.
Paul A Yushkevich, Joseph Piven, Heather Cody Hazlett, Rachel Gimpel Smith, Sean Ho, James C Gee, Guido Gerig. Neuroimage 2006
33

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
M Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, Stephen Damato, Dina Halai, Fitim Berisha, Robin Pollock, Paul O'Donnell, Anita Grigoriadis, Tim Diss,[...]. J Pathol 2011
638
33

Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
Akifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, Jacob Schlossman, Chencai Wang, Jingwen Yao, Catalina Raymond, Richard Everson, Kunal Patel, Sergey Mareninov,[...]. Neuro Oncol 2022
3
33

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Shimin Zhao, Yan Lin, Wei Xu, Wenqing Jiang, Zhengyu Zha, Pu Wang, Wei Yu, Zhiqiang Li, Lingling Gong, Yingjie Peng,[...]. Science 2009
856
33

Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
Martin J van den Bent, Marion Smits, Johan M Kros, Susan M Chang. J Clin Oncol 2017
95
33

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
Abigail R Molloy, Chloé Najac, Pavithra Viswanath, Aliya Lakhani, Elavarasan Subramani, Georgios Batsios, Marina Radoul, Anne Marie Gillespie, Russell O Pieper, Sabrina M Ronen. Theranostics 2020
13
33


Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
33

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward,[...]. Nature 2012
33

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
William D Tap, Victor M Villalobos, Gregory M Cote, Howard Burris, Filip Janku, Olivier Mir, Murali Beeram, Andrew J Wagner, Liewen Jiang, Bin Wu,[...]. J Clin Oncol 2020
43
33


IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
Philipp Kickingereder, Felix Sahm, Alexander Radbruch, Wolfgang Wick, Sabine Heiland, Andreas von Deimling, Martin Bendszus, Benedikt Wiestler. Sci Rep 2015
176
33

Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study.
Johann-Martin Hempel, Cornelia Brendle, Benjamin Bender, Georg Bier, Marco Skardelly, Irina Gepfner-Tuma, Franziska Eckert, Ulrike Ernemann, Jens Schittenhelm. J Neurooncol 2018
10
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.